There are an estimated 2.8 million new chlamydia infections each year in the US and 1.5 million new cases of gonorrhea diagnosed. The highest rates of both gonorrhea and chlamydia are reported in women aged 15 to 24. Symptoms are vague and sequelae can include pelvic inflammatory disease, ectopic pregnancy and infertility. A full comprehensive sexual history may identify other risk factors to prompt more comprehensive screening for sexually transmitted infections
Sexually transmitted infections (STIs) are common with potential for serious long term outcomes, and remain a serious public health concern. Here, we outline the recommendations for screening for STIs by population:
Gonorrhea and Chlamydia
The USPSTF 2021 Update: Chlamydia and Gonorrhea Screening
…recommends screening for chlamydia in all sexually active women 24 years or younger and in women 25 years or older who are at increased risk for infection. (B recommendation)
…recommends screening for gonorrhea in all sexually active women 24 years or younger and in women 25 years or older who are at increased risk for infection. (B recommendation)
The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for chlamydia and gonorrhea in men
Syphilis
HSV
Note: USPSTF “recommends against routine serologic screening for genital HSV infection in asymptomatic adolescents and adults, including those who are pregnant”
Trichomonas
Hepatitis B
Hepatitis C
HIV
CDC: Sexually Transmitted Infections Treatment Guidelines 2021
CDC: A Guide to Taking a Sexual History
CDC Recommendations for Hepatitis C Screening Among Adults — United States, 2020
CDC: Screening and Testing for Hepatitis B Virus Infection 2023
USPSTF: Screening for Chlamydia and Gonorrhea
USPSTF: Serologic Screening for Genital Herpes Infection
USPSTF: Recommendation: Human Immunodeficiency Virus (HIV) Infection Screening
Please log in to ObGFirst to access this page